News - EGFR exon 19 deletion

Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients (clinicaltrials.gov)

P2, N=54, Not yet recruiting, Shanghai Pulmonary Hospital, Shanghai, China

2 days ago

New P2 trial

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)

EGFR L858R • EGFR exon 19 deletion • ALK fusion

carboplatin • Loqtorzi (toripalimab-tpzi)

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) (clinicaltrials.gov)

P3, N=605, Active, not recruiting, Daiichi Sankyo | Trial completion date: Jan 2026 --> Feb 2027

5 days ago

Trial completion date

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET exon 14 mutation

docetaxel • Datroway (datopotamab deruxtecan-dlnk)

Towards identification of novel inhibitors of EGFR mutants through in-silico approach. (PubMed, Cancer Treat Res Commun)

Among the tested compounds, Tetrandrine, Dauricine, and Olmutinib exhibited robust binding affinities across both wild-type and mutant EGFR configurations, highlighting their potential as effective inhibitors. The integrated approach of combining molecular docking using CB-dock2, ADMET profiling, and Lipinski's rule of five provides a robust framework for preliminary drug candidate screening, potentially accelerating the development of more precise and effective EGFR-targeted therapies. The findings contribute to the growing body of research exploring alternative and more nuanced strategies for inhibiting EGFR-driven oncogenic mechanisms, highlighting the importance of computational methods in identifying novel molecular targets with improved specificity and reduced side effects.

5 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR wild-type

Olita (olmutinib) • CBT-1 (tetrandrine)

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC (clinicaltrials.gov)

P2, N=23, Recruiting, Taipei Veterans General Hospital, Taiwan | Not yet recruiting --> Recruiting | Trial completion date: Jun 2027 --> Dec 2027 | Trial primary completion date: Jun 2026 --> Dec 2026

5 days ago

Enrollment open • Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I

Tagrisso (osimertinib) • pemetrexed

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases (clinicaltrials.gov)

P=N/A, N=300, Active, not recruiting, Fudan University

5 days ago

New trial • Real-world evidence

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR positive

Tagrisso (osimertinib)

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)

P2/3, N=854, Recruiting, AbbVie | Trial completion date: Dec 2031 --> Nov 2036 | Trial primary completion date: Dec 2031 --> Nov 2036

6 days ago

Trial completion date • Trial primary completion date • Adverse events

MET (MET proto-oncogene, receptor tyrosine kinase)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion

cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • telisotuzumab adizutecan (ABBV-400)

Boosting osimertinib Blood Brain Barrier penetration in patients with epidermal growth factor receptor mutated non-small cell lung cancer (OSIBBBOOST) (2025-523033-26-00)

P1/2, N=14, Not yet recruiting, Academisch Ziekenhuis Maastricht

7 days ago

New P1/2 trial

EGFR (Epidermal growth factor receptor) • CD4 (CD4 Molecule)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion

Tagrisso (osimertinib)

Precision: Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib (clinicaltrials.gov)

P1/2, N=53, Not yet recruiting, Shanxi Province Cancer Hospital

9 days ago

New P1/2 trial • First-in-human

PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule)

EGFR mutation • PIK3CA mutation • EGFR L858R • EGFR exon 19 deletion • AKT1 mutation

Tagrisso (osimertinib) • Truqap (capivasertib)

Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion (clinicaltrials.gov)

P2, N=63, Not yet recruiting, Jiangmen Central Hospital

9 days ago

New P2 trial

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR positive

Ivesa (firmonertinib)

10d

Targeted and immunotherapy based on tissue of origin in carcinoma of unknown primary: a two-case report and literature review. (PubMed, Front Oncol)

Based on the above results, the patient received chemotherapy with carboplatin and pemetrexed disodium combined with targeted therapy using the EGFR tyrosine kinase inhibitor (TKI) almonertinib mesylate tablets. The two cases reported in this paper demonstrate that targeted and immune treatment plans based on the tissue of origin of the tumor can serve as a clinical option for patients with CUP. These findings may provide new information and references for clinical decision-making in the management of CUP.

10 days ago

Journal • IO biomarker

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • EGFR exon 19 deletion • ALK mutation

carboplatin • pemetrexed • Ameile (aumolertinib)

10d

Integrated analysis of therapeutic strategies and prognostic factors in advanced lung adenocarcinoma: Retrospective study with emphasis on gene assays, multimodality treatment approaches and predictive machine learning models. (PubMed, Oncol Lett)

First-line treatment with the tyrosine kinase inhibitor afatinib was associated with improved OS compared with that of patients treated with erotinib or gefitinib. In addition, combination therapy with the angiogenesis inhibitor bevacizumab had a positive impact on OS...These findings highlight the importance of molecular profiling and individualized treatment strategies in optimizing OS for patients with advanced lung adenocarcinoma. Furthermore, the validated machine learning models may serve as useful tools for risk stratification and personalized prognostic assessment to support clinical decision-making.

10 days ago

Retrospective data • Journal • PD(L)-1 Biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)

PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR expression • EGFR wild-type

Avastin (bevacizumab) • Gilotrif (afatinib) • gefitinib

10d

REVIVE: Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC. (clinicaltrials.gov)

P4, N=100, Not yet recruiting, AstraZeneca | Initiation date: Jan 2026 --> May 2026

10 days ago

Trial initiation date

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion

cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed